Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression

被引:205
作者
Ip, Michael S. [1 ]
Domalpally, Amitha
Hopkins, J. Jill [2 ]
Wong, Pamela [2 ]
Ehrlich, Jason S. [2 ]
机构
[1] Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Fundus Photograph Reading Ctr, Madison, WI 53717 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE; BLOOD-RETINAL BARRIER; BREAKDOWN; TRIAL; LASER;
D O I
10.1001/archophthalmol.2012.1043
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate effects of intravitreal ranibizumab on diabetic retinopathy (DR) severity over time in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) of ranibizumab for diabetic macular edema. Methods: Participants with diabetic macular edema (n=759) were randomized to monthly sham, 0.3-mg ranibizumab, or 0.5-mg ranibizumab intravitreal injections. Macular laser was available per protocol-specified criteria. Fundus photographs, taken at baseline and periodically, were graded by a central reading center; clinical examinations were performed monthly. The main outcome measures of this report are secondary/exploratory analyses including a 2-step or more and 3-step or more change on the Early Treatment Diabetic Retinopathy Study severity scale in the study eye and a composite DR progression outcome including photographic changes plus clinically important events such as occurrence of vitreous hemorrhage or need for panretinal laser. Results: At 2 years, the percentage of participants with DR progression (worsening by >= 2 or >= 3 steps) was significantly reduced in ranibizumab-treated eyes compared with sham-treated eyes, and DR regression (improving by >= 2 or >= 3 steps) was significantly more likely. The cumulative probability of clinical progression of DR as measured by the composite outcome at 2 years was 33.8% of sham-treated eyes compared with 11.2% to 11.5% of ranibizumab-treated eyes. Conclusions: Intravitreal ranibizumab reduced the risk of DR progression in eyes with diabetic macular edema, and many ranibizumab-treated eyes experienced improvement in DR severity. Because these results are exploratory, the use of intravitreal ranibizumab specifically to reduce DR progression or cause DR regression requires further study.
引用
收藏
页码:1145 / 1152
页数:8
相关论文
共 24 条
[21]  
Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
[22]   Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate [J].
Tolentino, MJ ;
Miller, JW ;
Gragoudas, ES ;
Jakobiec, FA ;
Flynn, E ;
Chatzistefanou, K ;
Ferrara, N ;
Adamis, AP .
OPHTHALMOLOGY, 1996, 103 (11) :1820-1828
[23]   Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression [J].
Wang, Kang ;
Wang, Yanling ;
Gao, Lixin ;
Li, Xinmin ;
Li, Mingming ;
Guo, Jianyou .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (08) :1541-1546
[24]   Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas [J].
Zhang, Xinynan ;
Bao, Shisan ;
Lai, Donna ;
Rapkins, Robert W. ;
Gillies, Mark C. .
DIABETES, 2008, 57 (04) :1026-1033